Oxford terminates trials of AstraZeneca COVID vaccine in children and adolescents due to coagulation problems.

Oxford University temporarily discontinued doses of COVID-19 vaccine developed with AstraZeneca PLC AZN.
-0.15%
AZN,
+ 0.15%
In a small UK study aimed at assessing safety and effectiveness in children and adolescents, it waited for more information on the rare clotting problem seen in a small group of adults who received it, the Wall Street Journal. Reported Tuesday The trial began in mid-February and involved more than 200 youngsters between the ages of 6 and 1

7, citing an Oxford spokesperson that the trial did not find any safety issues but concerns within the circle. Broad, and reviews of vaccines by UK and EU regulators are behind the movement, the European Medicines Agency previously said, it expects to update the public on investigations of blood clotting issues later in the week. this